MilliporeSigma, based in Sheboygan, Wis., has secured a Department of Defense (DoD) and Department of Health and Human Services (HHS) pact to establish domestic nitrocellulose membrane production capacity.
The $136.7 million contract would enable MilliporeSigma to expand its industrial base to establish nitrocellulose manufacturing capability while supporting more than 83.3 million tests per month for COVID-19 testing and future needs.
Nitrocellulose membrane is a critical material used in manufacturing SARS-CoV-2 rapid point-of-care tests with DoD’s Defense Assisted Acquisition Cell (DA2) spearheading the initiative in accordance with the Department of the Air Force’s Acquisition COVID-19 Task Force (DAF ACT).
Funding was provided via the American Rescue Plan Act (ARPA) to support domestic industrial base expansion for critical medical resources, per authorities.
Members of Congress recently paraded a mix of recommended updates to benefit military service members…
The ByteDance-owned TikTok faces an uphill battle in the United States after President Joe Biden…
Promising to grow space for integrating and delivering on critical defense programs by more than…
In unsealing a 13-page indictment this week, the U.S. Department of Justice (DOJ) revealed charges…
A bill targeting the illicit fentanyl supply chain, the Fentanyl Eradication and Narcotics Deterrence (FEND)…
In order to move the state closer to federal standards and allow reporting of local…
This website uses cookies.